Enanta Pharma (ENTA) Tops Q2 EPS by 12c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.45), $0.12 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $17.2 million versus the consensus estimate of $16.75 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Apple investigating exposure to Tata Electronics data breach, full analysis underway - Reuters
• Definium Therapeutics Inc (DFTX) PT Raised to $60 at Oppenheimer
• Expeditionary Energy's Future: Fewer Convoys, More Control